Summit Therapeutics Inc (SMMT)

Tentang perusahaan

Summit Therapeutics plc, formerly Summit Corporation plc, is a United Kingdom-based drug discovery and development company. The Company is engaged in developing drug candidates to treat Duchenne Muscular Dystrophy (DMD), a genetic disease, and Clostridium difficile Infection (CDI), an infectious disease. The Company is developing a pipeline of utrophin modulators that comprise its lead candidate SMT C1100 and next generation modulators that are at an earlier stage of development. SMT C1100 is in a Phase 1b clinical trial. The Company is developing SMT19969 as an antibiotic that is a potential treatment for initial CDI that could significantly reduce rates of recurrent disease. SMT19969 completed a Phase 1 clinical trial in healthy volunteers with the results showing it to be safe and well tolerated at all doses tested, including the expected therapeutic dose. The Company's subsidiaries include Summit (Oxford) Limited and Summit (Wales) Limited.